Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 10/20 | 0.63 |
| ▸ | HSD17B2 | P37059 | 10/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.62 |
| ▸ | SCD | O00767 | 1/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674579 | 0.85 | HSD17B1 (0.68) | HSD17B1HSD17B2CYP3A4CYP2C9SCD | |
| SCHEMBL8770634 | 0.82 | PTGS2 (0.68) | PTGS2CA12CA2CA9 | |
| SCHEMBL6168404 | 0.81 | CA2 (0.75) | HSD17B1HSD17B2CYP3A4CYP2C9PTGS2 | |
| SCHEMBL15771709 | 0.80 | PTGS2 (0.50) | PTGS2ENPP2CA12CA2CA9 | |
| SCHEMBL27621305 | 0.80 | ESR1 (0.62) | HSD17B1HSD17B2CYP3A4CYP2C9PTGS2 | |
| SCHEMBL29768635 | 0.80 | ESR1 (0.62) | HSD17B1HSD17B2CYP3A4CYP2C9PTGS2 | |
| SCHEMBL388018 | 0.80 | ENPP2 (0.86) | PTGS2SCDENPP2CA12CA2 | |
| SCHEMBL7898375 | 0.79 | HSD17B1 (1.00) | HSD17B1HSD17B2CYP3A4CYP2C9CA12 | |
| SCHEMBL25490780 | 0.79 | PTGS2 (0.53) | PTGS2CA12CA2CA9 | |
| SCHEMBL2225090 | 0.79 | FYN (0.77) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | HSD17B1 553/4885HSD17B2 821/4885CYP3A4 2004/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | HSD17B1 553/4885HSD17B2 821/4885CYP3A4 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.